- Trials with a EudraCT protocol (44,399)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,399 result(s) found.
Displaying page 1,759 of 2,220.
| EudraCT Number: 2022-002407-37 | Sponsor Protocol Number: BET-PSMA-121 | Start Date*: 2023-05-22 | |||||||||||
| Sponsor Name:Blue Earth Therapeutics Limited | |||||||||||||
| Full Title: An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with met... | |||||||||||||
| Medical condition: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-002047-29 | Sponsor Protocol Number: PI843_843_0080 | Start Date*: 2021-07-29 |
| Sponsor Name:CHU Amiens Picardie | ||
| Full Title: Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled trial | ||
| Medical condition: crohn disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-001514-18 | Sponsor Protocol Number: Cypher-TX_Pilot | Start Date*: 2022-09-12 |
| Sponsor Name:University Medical Center Ljubljana | ||
| Full Title: Cytomegalovirus Prophylaxis with Letermovir in Heart Transplant Recipients: A Non-randomized Cohort Pilot Study | ||
| Medical condition: The focus of investigation in the proposed study protocol is the rates of Cytomegalovirus viremia and/or disease in patients after heart transplantation undergoing novel CMV prophylaxis protocol us... | ||
| Disease: | ||
| Population Age: | Gender: Male, Female | |
| Trial protocol: SI (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-004165-20 | Sponsor Protocol Number: AITIK | Start Date*: 2023-04-26 | |||||||||||
| Sponsor Name:CHU de Poitiers | |||||||||||||
| Full Title: Discontinuation of Tyrosine Kinase Inhibitors in chronic myeloid leukemia and impact on the immune system: a randomized controlled trial of two therapeutic strategies | |||||||||||||
| Medical condition: | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-000597-29 | Sponsor Protocol Number: LTS13619 | Start Date*: 2015-09-30 | |||||||||||
| Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
| Full Title: An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients with Usher Syndrome type 1B | |||||||||||||
| Medical condition: Usher syndrome type 1B | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-000217-35 | Sponsor Protocol Number: EpSSG RMS 2005 | Start Date*: Information not available in EudraCT |
| Sponsor Name:Rikshospitalet-Radiumhospitalet HF | ||
| Full Title: EpSSG RMS 2005 a protocol for non metastatic rhabdomyosarcoma | ||
| Medical condition: Rhabdomyosarkom (RMS) er en kreftform utgående fra muskelvev. RMS kan oppstå hvor som helst i kroppen og rammer folk i alle aldre. Behandlingen av RMS består av cellegift, operasjon og/eller strål... | ||
| Disease: | ||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: NO (Ongoing) NL (Completed) BE (Completed) IT (Ongoing) GB (GB - no longer in EU/EEA) IE (Completed) ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-001732-38 | Sponsor Protocol Number: 1502 | Start Date*: 2015-09-14 | |||||||||||
| Sponsor Name:CENTRE OSCAR LAMBRET | |||||||||||||
| Full Title: EVALUATION OF SENTINEL NODE (SN) POLICY IN EARLY STAGE ENDOMETRIAL CARCINOMAS AT INTERMEDIATE AND HIGH RISK OF RECURRENCE: RANDOMIZED STUDY COMPARING SENTINEL NODE POLICY TO CURRENT FRENCH INITIAL ... | |||||||||||||
| Medical condition: Intermediate-risk endometrioïd carcinomas : IAg3, IB(II)g1-2 High-risk endometrioïd carcinomas : IB-II g3 High-risk non endometrioïd carcinomas : I-II | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-003600-41 | Sponsor Protocol Number: APHP200042 | Start Date*: 2022-01-25 |
| Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP) | ||
| Full Title: AMIloride for the treatment of Nephrogenic Diabetes insipidus for patients with bipolar disorder treated with lithium: a randomized controlled trial | ||
| Medical condition: NA | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-002686-15 | Sponsor Protocol Number: CHUBX2021/25 | Start Date*: 2022-10-18 |
| Sponsor Name:CHU de Bordeaux | ||
| Full Title: Effectiveness of an Optimisation Strategy for Emergency Tracheal Intubation on postintubation Morbidity: A cluster randomized controlled trial | ||
| Medical condition: respiratory distress | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-001813-35 | Sponsor Protocol Number: 2020/65 | Start Date*: 2022-04-21 | |||||||||||
| Sponsor Name:Centre Antoine Lacassagne | |||||||||||||
| Full Title: AGORA-1 /ALFA 2100 study : A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD relapse/refractory (R/R) AML | |||||||||||||
| Medical condition: Adult patients (aged 18 years old or more) with a newly diagnosis of relapsed/refractory (R/R) AML associated to the presence a FLT3 gene internal tandem duplication (FLT3-ITD). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-004038-12 | Sponsor Protocol Number: 19-01 | Start Date*: 2021-12-10 |
| Sponsor Name:CENTRE HOSPITALIER ANNECY GENEVOIS | ||
| Full Title: Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheter-related bloodstream infections due to Staphylococcus aureus | ||
| Medical condition: Staphylococcus aureus catheter bloodstream infection | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-003121-29 | Sponsor Protocol Number: D20180102 | Start Date*: 2020-03-04 |
| Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
| Full Title: Impact of Metformin on Peripheral Arterial Calcification in Type 1 Diabetes | ||
| Medical condition: Vascular calcification and type 1 diabetes | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-003627-38 | Sponsor Protocol Number: CD-2019/02 | Start Date*: 2019-11-12 | |||||||||||
| Sponsor Name:Centre Georges-François Leclerc | |||||||||||||
| Full Title: 18F-Fluorocholine (FCH) versus 18F-Fluorodesoxyglucose (FDG) PET/CT for the detection of lesions in patients with multiple myeloma | |||||||||||||
| Medical condition: Patient with multiple myeloma, addressed for initial evaluation and eligible for an autograft of Hematopoietic Stem Cells. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003560-31 | Sponsor Protocol Number: UKM18_0021 | Start Date*: 2020-01-29 | |||||||||||
| Sponsor Name:Universitätsklinikum Münster | |||||||||||||
| Full Title: A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) | |||||||||||||
| Medical condition: diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-004744-22 | Sponsor Protocol Number: GERICO11/PACS10 | Start Date*: 2013-05-27 | |||||||||||
| Sponsor Name:UNICANCER | |||||||||||||
| Full Title: Adjuvant systemic treatment for oestrogen-receptor (ER)-positive HER2-negative breast carcinoma in women over 70 according to Genomic Grade (GG): chemotherapy + endocrine treatment versus endocrine... | |||||||||||||
| Medical condition: oestrogen-receptor (ER)-positive HER2-negative breast carcinoma in women over 70 | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Female | ||||||||||||
| Trial protocol: BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-000784-23 | Sponsor Protocol Number: KKS-276 | Start Date*: 2020-11-17 | |||||||||||||||||||||
| Sponsor Name:Philipps-Universität Marburg | |||||||||||||||||||||||
| Full Title: The effects of esketamine and treatment expectation in acute major depressive disorder: a pharmacological fMRI-study (Expect) | |||||||||||||||||||||||
| Medical condition: To unravel the neural correlates of the interaction between positive expectation (high/low) and single dose antidepressant treatment (verum/placebo) with esketamine in patients with major depressiv... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2019-000561-20 | Sponsor Protocol Number: 020186 | Start Date*: 2020-02-28 |
| Sponsor Name:Tampere University Hospital | ||
| Full Title: Monitoring of neuromuscular blockade during general anaesthesia after reversal with neostigmine | ||
| Medical condition: We are studying reappearence of nondepolarizing neuromuscular block after it has been antagonized with a combination of neostigmine and glycopyrrolate. We are trying to find the incidence of the ph... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FI (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-006710-23 | Sponsor Protocol Number: Systher_1 | Start Date*: 2009-10-02 | ||||||||||||||||
| Sponsor Name:Blood Transfusion Centre of Slovenia | ||||||||||||||||||
| Full Title: Modulation of the immune response in patients with pancreatic tubular carcinoma | ||||||||||||||||||
| Medical condition: Pancreatic adenocarcinoma; after R0 or R1 resection and adjuvant gemcitabine treatment. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: SI (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2019-000300-16 | Sponsor Protocol Number: P170923J | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | |||||||||||||
| Full Title: NA | |||||||||||||
| Medical condition: NA | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-000188-38 | Sponsor Protocol Number: BUS-P3-02 | Start Date*: 2023-02-21 | |||||||||||
| Sponsor Name:Bellus Health, Inc. | |||||||||||||
| Full Title: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough In... | |||||||||||||
| Medical condition: Refractory or Unexplained Chronic Cough | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Trial now transitioned) SK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.